Philippines - English - FDA (Food And Drug Administration)

zuellig pharma corporation; distributor: zuellig pharma corporation - ketorolac trometamol - sterile ophthalmic solution - 5mg/ml (0.5% w/v)

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة العربية للمستحضرات الطبية والزراعية - arab company for medical & agricultural products - ketorolac tromethamine 0.4 % - 0.4%

Kenya - English - Pharmacy and Poisons Board

allergan pharmaceuticals (pty) ltd 30 new road (entrance off bavaria road), - ketorolac tromethamine - eye drops, solution - 5 mg/ml ketorolac tromethamine - ophthalmologicals: anti-inflammatory agents

Namibia - English - Namibia Medicines Regulatory Council

roche products sa (pty) ltd - ketorolac tromethamine - eye drops - each 1ml solution contains ketorolac tromethamine 5,0 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

mecca brands pty ltd -

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - aflibercept 40 mg/ml;   - solution for injection - 40 mg/ml - active: aflibercept 40 mg/ml   excipient: dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 20 sodium chloride sucrose water for injection - eylea (aflibercept) is indicated for the treatment of: · neovascular (wet) age-related macular degeneration (wet amd) · visual impairment due to macular oedema secondary to central retinal vein occlusion (crvo) · visual impairment due to macular oedema secondary to branch retinal vein occlusion (brvo) · diabetic macular oedema (dme) · visual impairment due to myopic choroidal neovascularisation (myopic cnv)

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - fingolimod hcl 0.56 mg eqv fingolimod - capsule - 0.5mg - fingolimod hcl 0.56 mg eqv fingolimod 0.5mg

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ranibizumab 10 mg/ml - solution for injection - 10 mg/ml - active: ranibizumab 10 mg/ml excipient: histidine histidine hydrochloride polysorbate 20 trehalose dihydrate water for injection - lucentis® is indicated for the treatment of neovascular (wet) age-related macular degeneration (amd).

Israel - English - Ministry of Health

novartis israel ltd - fingolimod as hydrochloride - hard capsule - fingolimod as hydrochloride 0.5 mg - fingolimod - fingolimod - gilenya is indicated for the treatment of patients with relapsing forms of multiple sclerosis ( ms ) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

Israel - English - Ministry of Health

novartis israel ltd - ranibizumab - solution for injection - ranibizumab 10 mg/ml - ranibizumab - ranibizumab - treatment of patients with neovascular (wet) age-related macular degeneration (amd). treatment of adult patients with visual impairment due to diabetic macular oedema (dme) . the treatment of visual impairement due to macular oedema secondary to retinal vein occlusion (rvo). the treatment of visual impaiment due to choroidal neovascularization (cnv) . lucentis is indicated in preterm infants for: the treatment of retinopathy of prematurity (rop) with zone i (stage 1+, 2+, 3 or 3+), zone ii (stage 3+) or ap-rop (aggressive posterior rop) disease.the treatment of proliferative diabetic retinopathy (pdr)